Where does Endostream Medical Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Endostream Medical Ltd. ranks #35,191 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Endostream Medical Ltd. hold?

Endostream Medical Ltd. holds 7 US utility patents granted between 2020 and 2025, spanning 2 technology areas.

What is Endostream Medical Ltd.'s Innovation Score?

Endostream Medical Ltd. has an Innovation Score of 38.0 out of 100 (top 42% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Endostream Medical Ltd. focus on?

Endostream Medical Ltd.'s top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 7 patents, ranking #2,341 of 7,127 assignees active in that subclass. Grants appear in 2 CPC subclasses total.

Is Endostream Medical Ltd.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Endostream Medical Ltd..

What does claim depth mean for Endostream Medical Ltd.'s patents?

Endostream Medical Ltd.'s patents average 20.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Endostream Medical Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Endostream Medical Ltd.

USPTO PatentsView assignee record - 7 granted patents across 2 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Endostream ranks #35,191 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 2 technology areas.

#35,191
of 49,997 US assignees by volume: Top 42%
by Innovation Score (38.0/100): 20.9
avg claims per patent

USPTO PatentsView assignee plate

Corpus R35191 · Foreign Corporation #35,191 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 7 grants
MID-PACK #35,191/49,997
PHOTO-FINISH Emplase Medical
CPC-NARROW A61B · 2 areas
INNOV-THIN 38.0/100
CLAIMS-DENSE 20.9 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2020–2025 · 6y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Emplase Medical Technologies, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Endostream’s 38.0 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.2 pts (19%) Velocity 13.3 pts (35%) Breadth 5.0 pts (13%) Claim depth 12.5 pts (33%)

Qualcomm Incorporated · highest

85
Endostream Medical · this assignee

38
3D Lighting… · lowest

7

What this shows Endostream's Innovation Score is 38.0/100 (top 42% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Endostream?

Each dot is one of Endostream’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Endostream’s own 20.9 claims/patent is ABOVE the 16.4 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Endostream vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Endostream's grants concentrate

Endostream Medical Ltd. is a focused PatentsView assignee: 2 CPC subclasses with 100% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2023 (2 grants) versus a trough of 1 in 2020. By volume, Endostream sits between Emplase Medical Technologies, LLC and Enyo Pharma.

Endostream's three-year grant acceleration

Endostream Medical Ltd. shows 4 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Emplase Medical

7
Emplicure AB

7
Emza Visual Sense

7
Endocontrol

7
Enea Agenzia Nazi…

7
Energy Control

7
Enpress

7
Enyo Pharma

7
Endostream Medical ◀

7

What this shows Endostream holds 7 patents at rank #35,144, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Endostream

By rank, the assignees closest to #35,144 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Endostream's primary technology class.

Endostream's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

38 Top 42% higher than 58% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

Endostream Medical Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	1	14.3%
2021	1	14.3%
2023	2	28.6%
2024	2	28.6%
2025partial year	1	14.3%

Which technologies does Endostream Medical Ltd. patent most?

A61B - DIAGNOSIS; SURGERY; Identification 7

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 2

Top 2 of 2 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Endostream Medical Ltd.'s patent record in context - here's where to go next.

Endostream Medical Ltd.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 100% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #35,191 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Endostream Medical Ltd. against Emplase Medical Technologies, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 38.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.